CUPERTINO, Calif., Jun 5, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Specialty Pharmaceuticals Conference. The conference is taking place June 5-6, 2002 at the Grand Hyatt New York. Thomas A. Schreck, Chief Financial Officer will be presenting at the conference on Thursday, […]
CUPERTINO, Calif., Apr 29, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place May 1-2, 2002 at The Millennium Hotel in New York. Dr. Felix Theeuwes, Chairman & Chief Scientific Officer will be
CUPERTINO, Calif., Apr 24, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2002. DURECT’s net loss for the three months ended March 31, 2002 was $9.7 million or 20 cents per share, compared to $4.9 million or 11 cents per share for the
DURECT Corporation Reports First Quarter 2002 Financial Results Read More »
CUPERTINO, Calif., Apr 8, 2002 (BUSINESS WIRE) — In conjunction with DURECT Corporation’s (Nasdaq:DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, April 24, 2002 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive Officer, Tom
DURECT Corporation Invites You to Join its First Quarter 2002 Conference Call on the Web Read More »
CUPERTINO, Calif., Apr 2, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has filed an Investigational New Drug application to investigate the delivery of cromolyn sodium for the treatment of asthma. This IND was filed as part of an ongoing program to develop a product for the treatment of asthma
DURECT Corporation Files IND for the Long Term Treatment of Asthma Read More »
CUPERTINO, Calif., Mar 27, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today a collaboration with Cardinal Health (NYSE: CAH) Pharmaceutical Technologies and Services Center, Inc. to explore the feasibility of producing long acting soft gelatin based oral products, using the SABER(TM) technology as core formulations. The technology has the potential of greatly
CUPERTINO, Calif., Mar 18, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today the results from a pilot Phase III clinical study for its lead product in development, the CHRONOGESIC(TM) (sufentanil) Pain Therapy System for the treatment of chronic pain. The CHRONOGESIC product is undergoing clinical investigation for the treatment of stable, opioid
CUPERTINO, Calif., Jan. 30 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2001. The Company’s net loss attributable to common stockholders for the three months ended December 31, 2001 was $10.1 million or 21 cents per share, compared to $4.9 million or 11 cents
DURECT Corporation Reports Fourth Quarter 2001 and Year End Financial Results Read More »
CUPERTINO, Calif., Jan. 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it is sponsoring a symposium on novel drug delivery technologies at the 45th Annual Meeting of the Western Pharmacology Society (WPS) being held at the Hotel El Cid in Mazatlan, Sinaloa, Mexico, January 27th through February 1st, 2002. Dr. Randolph M. Johnson,
CUPERTINO, Calif., Jan 14, 2002 (BUSINESS WIRE) — In conjunction with DURECT Corporation’s (NASDAQ:DRRX) fourth quarter and year end 2001 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, January 30, 2002 at 4:30 p.m. EDT with Jim Brown, President and
